Mr. Jim Hutchens reports
IMAGIN MEDICAL RESEARCH STUDY BEGINS
Imagin Medical Inc., as a
follow-up to the announcement dated Nov. 29, has released additional information
concerning the research study using the i/Blue imaging system being conducted at
the University of Rochester Medical Center.
As of today, initial subjects have been recruited and procedures are being
co-ordinated with the lead investigator's surgical schedule. During the 10-subject
research study, Imagin's development team will work with the surgical staff to
evaluate outcomes and adjust system components as needed to optimize product
performance. "We are excited to see the study under way and are fortunate to be
working with the University of Rochester, one of the nation's leading academic
medical centres, on this important step forward for Imagin," said Jim Hutchens,
Imagin's president and chief executive officer.
Demonstrating feasibility of the technology and defining the parameters for success
will be followed by thorough assessment and refinement of all components for
technical and cost-efficiency. Progress will be reported as information becomes
available. Imagin anticipates all 10 procedures will be completed within four months,
with the study remaining open for an additional nine months for subject follow-up.
All updates will be published by the University of Rochester on the government's Clinical Trials website according to the research study guidelines.
The purpose of the study is to validate previous bench testing results that showed
the i/Blue imaging system technology will enable physicians to "see" the cancer in
less than 15 minutes versus the full hour required by today's technology, as well as
blend the white and florescence images into one, placing the cancer in context within
the bladder.
About Imagin Medical Inc.
Imagin Medical is developing imaging solutions for the early detection of cancer during
minimally invasive surgeries. The company believes it will radically improve the way
physicians detect cancer. Imagin's initial target market is bladder cancer, a major cancer
worldwide, the sixth-most prevalent in the United States, and the most costly cancer to treat due
to a greater than 50-per-cent recurrence rate. Developed at the Lawrence Livermore National
Laboratory, this advanced, ultrasensitive imaging technology is based upon improved
optical designs and advanced light sensors.
We seek Safe Harbor.
© 2024 Canjex Publishing Ltd. All rights reserved.